[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583991":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":11,"armGroups":23,"interventions":35,"overallOfficials":50,"centralContacts":54,"locations":60,"responsibleParty":77,"collaborators":11,"id":79,"slug":11,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":11,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":11,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":94,"conditions":95,"keywords":11,"overallStatus":63,"whyStopped":11,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Objective response rate (ORR)",null,"Up to 2 years",[14],{"measure":15,"description":16,"timeFrame":12},"Immunogenicity","Incidence of antidrug antibodies (ADA)",{"allocation":18,"interventionModel":19,"interventionModelDescription":11,"primaryPurpose":20,"observationalModel":11,"timePerspective":11,"maskingInfo":21},"RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":22,"maskingDescription":11,"whoMasked":11},"NONE",[24,31],{"label":25,"type":26,"description":27,"interventionNames":28},"Part 1: Plan A","EXPERIMENTAL","ZG005（20mg\u002Fkg Q3W）+Gecacitinib（Gecacitinib is administered continuously until the end of treatment）",[29,30],"Biological: ZG005 for Injection","Drug: Gecacitinib Hydrochloride Tablets",{"label":32,"type":26,"description":33,"interventionNames":34},"Part 1: Plan B","ZG005（20mg\u002Fkg Q3W）+Gecacitinib（Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21）",[29,30],[36,43],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"BIOLOGICAL","ZG005 for Injection","intravenous infusion",[25,32],[42],"ZG005",{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"DRUG","Gecacitinib Hydrochloride Tablets","Oral",[25,32],[49],"Gecacitinib",[51],{"name":52,"affiliation":5,"role":53},"Jason Wu","STUDY_CHAIR",[55],{"name":56,"role":57,"phone":58,"phoneExt":11,"email":59},"Shuangyu Jia","CONTACT","+86-0512-57018310","jiasy@zelgen.com",[61],{"facility":62,"status":63,"city":64,"state":65,"zip":11,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"The First Affiliated Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","China","CN",{"type":69,"coordinates":70},"Point",[71,72],120.16142,30.29365,{"lat":72,"lon":71},[75],{"name":76,"role":57,"phone":11,"phoneExt":11,"email":11},"Jie Jin",{"type":78,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100583991",false,"NCT06883526","Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I\u002FII Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","Inclusion Criteria:\n\n* Fully understand this study and voluntarily sign the ICF；\n* Age ≥18 at ICF signing, regardless of gender；\n* Histologically confirmed relapsed or refractory lymphoma.\n\nExclusion Criteria:\n\n* Lymphoma with known CNS involvement；\n* Severe cardiovascular\u002Fcerebrovascular diseases.\n* Any other reason deeming the participant unsuitable for the study, as judged by the investigator.","ALL","18 Years",{"count":88,"type":89},60,"ESTIMATED","INTERVENTIONAL",[92,93],"PHASE1","PHASE2","PART 1:\n\n1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.\n2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma.\n\nPART 2:\n\nTo evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.",[96],"Lymphoma","2025-12-30",{"date":99,"type":100},"2026-01-05","ACTUAL",{"date":102,"type":100},"2025-05-16",{"date":104,"type":89},"2027-05",{"name":5,"class":6},1]